Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


Investor Relations

NASDAQ : STML

$10.96 - 0.32
Volume: 89,000
Sep 2, 2014 2:31 PM ET
Delayed at least 20min., by eSignal.

Stock price graph
     

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk in a variety of cancer types. Stemline is currently developing two clinical-stage product candidates, SL-401 and SL-701.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-401 has demonstrated single-agent activity, including durable complete responses (CRs), in a Phase 1/2 trial in several indications including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed or refractory acute myeloid leukemia (AML). SL-401 is being advanced into programs in BPDCN and other rare IL-3R+ malignancies, as well as additional hematologic cancers including AML and myeloma.

SL-701 is an enhanced immunotherapy that activates the immune system to attack tumors. An earlier version of this therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in advanced adult and pediatric brain cancers. SL-701 is being advanced into trials of adults with glioblastoma multiforme (GBM) at first recurrence, and children with non-brainstem and brainstem glioma.

Additionally, Stemline has built a robust preclinical pipeline, which includes next generation IL-3R-targeted compounds, SL-501 and SL-101, an innovative discovery platform, and an extensive intellectual property portfolio including some of the earliest patents in the CSC area.



Corporate Snapshot

PDF Corporate Snapshot


Corporate Presentation

PDF Corporate Presentation – August 2014

View all »   RSSRecent Releases

Aug 14, 2014
Stemline Therapeutics Provides Second Quarter 2014 Financial Results and Corporate Update

Aug 5, 2014
Stemline Therapeutics to Present at the Wedbush Life Sciences Management Access Conference


View all »Events & Presentations

There are no upcoming events at this moment.



Copyright 2014 - Stemline Therapeutics, Inc. All rights reserved
Stemline